In early discovery and development, accurate bioanalytical methods, combined with CMC manufacturability, are essential for driving molecule screening and assessing developability within a DMPK/ADME framework.

In this webinar, we will present case studies spanning multiple novel modalities including antibodies, bispecific antibodies, ADC (Antibody Drug Conjugate), and APC (Antibody Peptide Conjugate) therapeutics. The presentation will focus on three key areas:

LC-MS/MS, ELISA, and Gyrolab as comparable bioanalytical methods for ADC and antibody PK analysis
Transgenic mouse PK as a rapid screening approach
ADME screening strategies for peptides, linkers, and payloads in ADC programs
These case studies demonstrate how an integrated DMPK/ADME platform can accelerate preclinical screening and improve decision-making for early-stage large-molecule programs. While bioanalysis of biologics and conjugated therapeutics presents unique challenges due to matrix complexity, molecular heterogeneity, and evolving analytical requirements, innovative bioanalytical strategies can generate robust, reliable data that enable confident candidate selection and successful program progression.